Drugs / 19UCART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07316907 | Dec 2025 → Jun 2027 expected | lymphoma | YANRU WANG | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 19UCART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07316907 ↗ |
| Action | Deplete | “ability of 19UCART to deplete CD19 positive cells” NCT07316907 ↗ |
| Modality | Cell therapy | “19UCART injection is a CD19-targeted allogenic CAR-T.” NCT07316907 ↗ |
| Route | Intravenous | “administered intravenously” NCT07316907 ↗ |
| Target | CD19 | “19UCART injection is a CD19-targeted allogenic CAR-T.” NCT07316907 ↗ |